COVID-19 and thrombosis: From bench to bedside

• Published in: Trends in cardiovascular medicine Vol. 31; no. 3; pp. 143 - 160
• Main Authors: Ali, Mohammad A.M., Spinler, Sarah A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-04-2021; Elsevier Limited; Elsevier Science Publishing
• Subjects: Anticoagulants - therapeutic use; Antioxidants; Blood platelets; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - diagnosis; COVID-19 Drug Treatment; Disease; Drug therapy; Endothelium; Fibrinolytic Agents - therapeutic use; Hospitalization; Humans; Infections; Influenza; Intensive care; Lungs; Multisystem inflammatory syndrome in children; Nitric oxide; Oxidative stress; SARS-CoV-2 - pathogenicity; Severe acute respiratory syndrome coronavirus 2; Thromboembolism; Thromboembolism - drug therapy; Thromboembolism - virology; Thrombosis; Thrombosis - diagnosis; Thrombosis - drug therapy; Thrombosis - virology
• ISSN: 1050-1738; 1873-2615
• DOI: 10.1016/j.tcm.2020.12.004

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19.